Novartis Ag

University of Pennsylvania

Harvard College

Dana-farber-cancer Institute Inc.

Engels, Boris

Boris Engels

Jennifer Brogdon

Brian Walter Granda

Andreas Loew

Huijuan Song

Carla Guimaraes

Lu Huang

Carl H June

Ming Lei

Michael C Milone

Qilong Wu

Jimin Zhang

Na Li

Neeraja Idamakanti

Gregory Beatty

Saar Gill

Barbara Brannetti

Marco Ruella

Regina M Young

Gordon James Freeman

Gerhard Johann Frey

Hwai Wen Chang

Arlene Helen Sharpe

David Jonathan Glass

Joan Mannick

Jennifer Marie Mataraza

Brian Edward Vash

Leon Murphy

Jan Weiler

Reshma Singh

Li Zhou

Enxiu Wang

William Raj Sellers

John Hastewell

Glenn Dranoff

Chonghui Zhang

Tony Fleming

Connie Hong

Aida Abujoub

Brian Holmberg

John Blankenship

Dexiu Bu

Xu Zhu

Michael R Greene

Carla Patricia Pinto Guimaraes

Louise Treanor

Andrew Price

Joni Waiee Lam

Anniesha Hack

Serena De Vita

Hyungwook Lim

Elizabeth Dorothy Pratico

Olja Kodrasi

Attilio Bondanza

Akash Sohoni

Andrew Marc Stein

The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.

Chimeric antigen receptors and uses thereof

The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and/or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and/or CD19, methods of making a cell comprising the same and vectors encoding the same.

CD19 and CD22 chimeric antigen receptors and uses thereof

Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy

Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.

Human mesothelin chimeric antigen receptors and uses thereof

The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a 'NKR-CAR' which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).

Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain

Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain

Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

Regulatable chimeric antigen receptor

Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor(CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.

Growing community of inventors

Arlington, MA, United States of America

Boris Engels